Engineered vesicle for targeted editing of T cells as well as preparation method and application of engineered vesicle
By constructing targeted vesicles loading in T cells and loading CRISPR system to edit the DUSP2 gene, the problem of T cell depletion in liver cancer patients was solved, T cell reactivation and tumor cell killing effect were achieved, and a gene drug was provided for Immunotherapy for liver cancer.
Patent Information
- Application Number
- CN202411100506.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-22
AI Technical Summary
Patients with liver cancer are insensitive to chemotherapy, T cells are easily depleted in the liver cancer microenvironment, and the existing technology is difficult to effectively restore their killing ability. The CRISPR/Cas9 gene editing tools lack safe and efficient delivery vehicles, which limits their clinical applications.
By constructing engineered vesicles targeting T cells with high expression of PD-1, loading into the CRISPR system and sgRNA, the DUSP2 gene was edited to reverse the depletion state of T cells and enhance its killing effect.
Successfully promotes the acquisition of stem characteristics of CD8+ T cells, CD4+ T cells enhance auxiliary functions, secrete interferon-like effector factors, and jointly enhance tumor cell killing effect, providing a gene drug that enhances anti-tumor immunotherapy for liver cancer.
Smart Images

Figure CN118987280A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of gene drug delivery, and specifically relates to an engineered vesicle for targeted editing of T cells and a preparation method and application thereof. Background Art
[0002] Liver cancer is highly malignant, progresses rapidly, has a poor prognosis, and has a low 5-year survival rate. Most liver cancer patients are insensitive to chemotherapy, and single targeted therapy has limited benefits.
[0003] As the main organ of metabolism, the liver has immunosuppressive polarity and can weaken T cell-mediated antigen response. In addition, continuous antigen stimulation, immunosuppressive cells and immune checkpoints in the tumor microenvironment will significantly weaken the infiltration and effector function of T cells. Studies have shown that there are a large number of tumor tissue-specific tumor infiltrating lymphocytes (TILs) in liver cancer tissue, but most of these T cells are in an exhausted state (T ex ) and have a tendency to further develop into suppressor T cells. ex The decline in cell effector function and proliferation capacity is highly correlated with the overexpression of inhibitory receptors such as programmed cell death (PD)-1. Blocking the PD-1 pathway has opened up a new therapeutic approach for reactivating T cell responses. However, blocking PD-1 / PD-L1 can benefit some patients, but it cannot "awaken" the T cells of all patients. Therefore, further utilizing the large number of tumor antigen-specific TILs in liver cancer tissues to block their exhaustion or reverse their exhausted phenotype and restore their tumor killing ability is a key point in liver cancer immunotherapy.
[0004] DUSP2, also known as phosphatase PAC1, was found to be highly expressed in lymphocytes, especially in exhausted TILs, and negatively correlated with the survival of cancer patients. DUSP2 can serve as an epigenetic checkpoint to regulate T cell responses and is also a potential target for cancer immunotherapy.
[0005] As a precise genome editing tool, CRISPR / Cas9 is applicable to a variety of organisms and cell types. It can directly and selectively modify the genome, transcriptome and epigenome, effectively promoting the exploration of basic biological functions and the discovery and verification of potential drug targets for complex genetic diseases, opening up a new direction in the field of cancer treatment. However, the lack of safe and efficient delivery vectors has limited its clinical application. Summary of the invention
[0006] To solve the above problems, the present invention discloses an engineered vesicle for targeted editing of T cells and its preparation method and application. Through extracellular vesicles (EVs), the CRIPSR gene editing system is delivered to edit the DUSP2 gene in T cells with high expression of PD-1 and exhaustion potential, so that the exhausted T cells regain stem-like characteristics and further stimulate them to become killer T cells, thereby enhancing the tumor cell killing effect.
[0007] To achieve the above object, the technical solution of the present invention is as follows:
[0008] In a first aspect, the present invention provides an engineered vesicle for delivering CRISPR gene editing tools, comprising a lipid bilayer and a Cas protein of the CRISPR system, wherein the Cas protein enters the vesicle by overexpression in donor cells.
[0009] Furthermore, according to the engineered vesicles for delivering CRISPR gene editing tools of the present invention, the guide RNA (sgRNA) targeting the target gene DUSP2 is loaded into the vesicles by electrotransfection.
[0010] Furthermore, the engineered vesicles are obtained by expression and separation of engineered cells transfected with a recombinant expression vector, wherein the recombinant expression vector comprises at least a first recombinant plasmid and a second recombinant plasmid.
[0011] Furthermore, the Cas protein includes Cas9 protein or a mutant thereof.
[0012] Furthermore, the host cells include HEK293T cells.
[0013] Furthermore, the targeting peptides include human PD-1 targeting peptides and mouse PD-1 targeting peptides.
[0014] Second, the present invention also provides a method for preparing engineered extracellular vesicles for targeted editing of T cells, which comprises the following steps:
[0015] (1) Construction of Cas9 overexpressing cell lines: The recombinant plasmid encoding Cas9 protein and the viral packaging plasmid were co-transfected into HEK-293T cells, the virus was obtained and then infected into the host cells, and culture and drug screening were performed to screen out the cell line that stably overexpressed Cas9 protein (Cas9 / HEK293T).
[0016] (2) Construction of a recombinant vector: The nucleic acid sequence of the fusion protein of the targeting peptide-transmembrane protein targeting PD-1 was connected to construct a recombinant plasmid (plenti TPCLG).
[0017] (3) The above-mentioned fusion protein recombinant plasmid (plenti TPCLG) and the virus packaging plasmid were co-transfected into Cas9 / HEK293T cells, and the virus was obtained to infect the host cells, and culture and drug screening were performed to screen out a stable engineered donor cell line (TPCLGC9-293).
[0018] (4) isolating engineered extracellular vesicles from the stable engineered donor cell line screened in step (3), and loading the sgRNA into the vesicles by electroporation.
[0019] Furthermore, in step (2), the targeting peptide targeting PD-1 includes a human PD-1 targeting peptide and a mouse PD-1 targeting peptide.
[0020] Furthermore, the method does not include the step of using a viral packaging vector.
[0021] Furthermore, the sgRNA is a recombinant plasmid, including integrating a target sequence targeting a target gene into the recombinant plasmid.
[0022] Third, the present invention also provides a system for targeted reprogramming of exhausted T cells, which comprises the engineered extracellular vesicles and virus-like packaging vectors described above in the present invention.
[0023] Fourth, the present invention also provides a method for performing gene editing in cells, comprising the step of using the engineered extracellular vesicles according to the present invention to deliver CRISPR and sgRNA into target cells.
[0024] Fifth, the present invention also provides a reagent for use in the preparation of a gene drug for enhancing anti-tumor immunotherapy of liver cancer, wherein the reagent includes the engineered extracellular vesicles described in the present invention.
[0025] Further, according to the use of the present invention, the Cas9 protein and sgRNA can specifically act on the target DNA sequence DUSP2 and exert a gene editing function.
[0026] The beneficial effects of the present invention are:
[0027] The present invention utilizes engineered vesicles, namely, the transmembrane protein LAMP2 is used to anchor the PD-1 targeting peptide on the surface of the engineered vesicles, so that it can specifically target T cells with high PD-1 expression and exhaustion potential, deliver the CRISPR / Cas9 system, downregulate the expression of DUSP2, and effectively promote CD8 + T cells acquire stemness characteristics and reverse the exhausted phenotype; at the same time, they effectively promote CD4 + T cells play an auxiliary function, secrete effector factors such as interferon (IFN-γ), regulate the immune microenvironment, and synergistically enhance the tumor cell killing effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 Construction of engineered EVs delivery system fusion plasmid and donor cell line; (A) Schematic diagram of LAMP2-based engineered EVs fusion plasmid; (B) Fluorescence image of engineered donor cell line stably transfected with the above plasmid (green is LAMP2-AcGFP / TPCLG fusion fluorescent protein); Standard ruler: 200μm.
[0029] Figure 2 Characterization of engineered EVs; (A) Schematic diagram of the separation and purification process of engineered EVs; (B) TEM, (C) DLS and (D) NTA characterization of purified engineered EVs; Standard ruler: 100 nm; (E) WB detection of the expression of specific marker proteins of engineered EVs; CD40 is the surface marker protein of engineered EVs (medium-sized particles, microvesicles), AcGFP is the detection marker of fusion proteins, and Flag is the detection marker of Cas9 protein;
[0030] Figure 3 Engineered EVs mediate PD-1 specific targeting; (A&B) Flow cytometry detection of engineered EVs being targeted by PD-1 in an induced exhausted T cell model - / + Cell uptake efficiency; engineered EVs have AcGFP tags with green fluorescence, and PD-1 high-expressing cells are marked by anti-PD-1-PerCP flow cytometry antibody staining; (C) Small animal imaging IVIS shows the in vivo distribution of the two engineered EVs in tumor-bearing mice; the red circle is the tumor site; (D) Quantified histogram of fluorescence intensity at the mouse tumor site; *p<0.05, **p<0.01, ***p<0.001;
[0031] Figure 4 Construction of an in vitro induced exhausted T cell model; (A) Schematic diagram of the induced exhausted T cell model using Dynabeads (CD3 / CD28 coupled magnetic beads); (B&C) ELISA to detect the secretion levels of IFN-γ and IL-2 effector factors in the culture medium after each stimulation; (D) Flow cytometry to detect the expression levels of cell exhaustion markers PD-1 and TIM3 after multiple magnetic bead stimulations;
[0032] Figure 5 Engineered EVs-mediated gene editing of exhausted T cells; (A) T7E1 and (B) WB analysis of the editing effects of different sgRNA sequences on the target gene DUSP2; (D) Flow cytometry analysis of the regulation of engineered EVs-mediated DUSP2 editing on the expression of PD-1 in induced exhausted T cells; (EG) ELISA detection of the secretion level of related effector factors in the cell culture supernatant; (H) Fluorescence quantitative PCR analysis of the relative expression levels of related marker proteins in the cells after treatment;
[0033] Figure 6 To engineer EVs to enhance the killing effect of liver cancer cells in vitro. DETAILED DESCRIPTION
[0034] The present invention will be further explained below in conjunction with the accompanying drawings and specific embodiments. It should be understood that the following specific embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0035] Engineered extracellular vesicles
[0036] The present invention provides an engineered vesicle for delivering CRISPR gene editing tools, comprising a lipid bilayer and a Cas9 protein of the CRISPR system, wherein the Cas9 protein enters the vesicle by overexpression of donor cells. The engineered cell vesicle of the present invention is a medium-sized vesicle, and the particle size is generally between 50-300 nm.
[0037] The engineered extracellular vesicle of the present invention has a lipid bilayer structure. The lipid bilayer contains an overexpressed transmembrane protein LAMP2, and a fused targeting peptide structure is disposed on the outside of the lipid bilayer. In certain embodiments, the targeting peptide is a targeting peptide of human PD-1.
[0038] In the present invention, the CRISPR system finally delivered includes Cas9 protein and sgRNA plasmid. In certain embodiments, the sgRNA plasmid is loaded into the vesicle by electrotransfection.
[0039] In an exemplary embodiment, the Cas9 protein of the present invention is directly produced by an overexpression plasmid and enters the engineered extracellular vesicle of the present invention. The sgRNA plasmid is loaded into the vesicle by electrotransfection. In another exemplary embodiment, the present invention can use, for example, artificially prepared sgRNA and introduce it into the engineered extracellular vesicle by other artificial means.
[0040] In a preferred embodiment, the engineered extracellular vesicles of the present invention contain Cas9 protein, but do not contain a gene for expressing the Cas9 protein. For example, the engineered extracellular vesicles of the present invention do not contain any expression vector or plasmid for producing the delivery system. That is, preferably, the engineered extracellular vesicles of the present invention have a determined amount of Cas9 protein, and the vesicles themselves cannot produce new Cas9 protein by transcription or translation.
[0041] In an exemplary embodiment, the engineered extracellular vesicles of the present invention are endogenous microvesicles, which are obtained by cell secretion. Therefore, in addition to the above-mentioned Cas9 protein, it also contains proteins contained in the microvesicles themselves and corresponding mRNA, miRNA, etc.
[0042] In addition to the above-mentioned Cas9 protein, the engineered extracellular vesicles of the present invention also include other components, for example, targeting peptides and transmembrane fusion proteins that guide the engineered extracellular vesicles to target and exhaust T cells. In certain embodiments, the targeting peptide is composed of a human PD-1 targeting peptide. Among them, the transmembrane protein can be replaced by other transmembrane proteins known in the art, and the targeting peptide can also be replaced by a targeting peptide of other exhaustion markers in the art.
[0043] Those skilled in the art will appreciate that the engineered vesicles for CRISPR gene editing tools of the present invention may also include other elements for gene expression, such as but not limited to promoters, linkers (flexible linker arms), etc., and may also include reporter groups for protein labeling and tracing, without particular limitation.
[0044] The engineered vesicles for delivering CRISPR gene editing tools of the present invention can be prepared by any method in the art. For example, an artificial synthesis method or a cell culture-based method. A detailed description of the cell culture-based method is provided below.
[0045] Method for preparing engineered extracellular vesicles
[0046] A second aspect of the present invention provides a method for preparing an engineered extracellular vesicle, comprising the following steps:
[0047] (1) Construction of Cas9 overexpressing cell lines: The recombinant plasmid encoding Cas9 protein and the viral packaging plasmid were co-transfected into HEK-293T cells, the virus was obtained and then infected into the host cells, and culture and drug screening were performed to screen out the cell line that stably overexpressed Cas9 protein (Cas9 / HEK293T).
[0048] (2) Construction of a recombinant vector: The nucleic acid sequence of the fusion protein of the targeting peptide-transmembrane protein targeting PD-1 was connected to construct a recombinant plasmid (plenti TPCLG).
[0049] (3) The above-mentioned fusion protein recombinant plasmid plenti TPCLG and the virus packaging plasmid were co-transfected into Cas9 / HEK293T cells, and the virus was obtained to infect the host cells, and culture and drug screening were performed to screen out stable engineering donor cell lines.
[0050] (4) Isolate engineered extracellular vesicles and load sgRNA into the vesicles by electroporation.
[0051] In the present invention, the vectors used in steps (1) and (2) are lentiviral vectors (plenti series). In certain embodiments, for example, pCDH vectors are used for gene overexpression, and the preferred vector is a lentiviral vector.
[0052] In the present invention, the conditions for culturing in step (3) are known in the art, including appropriate culture time, temperature and carbon dioxide concentration, etc. The donor cells need to have the function of secreting extracellular vesicles. In a preferred experimental scheme, HEK-293T cells are the donor cell line.
[0053] In the present invention, the separation of engineered extracellular vesicles in step (4) can be carried out by culture fluid of engineered cells, and the culture supernatant of the present invention contains engineered extracellular vesicles secreted from engineered cells and culture medium components. The purpose of step (4) is mainly to separate the desired engineered extracellular vesicles from culture medium components, etc. The separation in step (4) is sometimes also referred to as extraction or enrichment, examples of which include but are not limited to differential centrifugation, density gradient centrifugation, ultrafiltration centrifugation, magnetic bead immunoassay, etc. The separation in step (4) can also be performed by using a known kit.
[0054] Methods for editing genes in cells
[0055] The third aspect of the present invention provides a method for performing gene editing in cells, comprising the step of delivering the CRISPR gene editing system into target cells using the engineered extracellular vesicles according to the first aspect of the present invention. The target cells of the present invention refer to exhausted T cells with high expression of PD-1.
[0056] Use of engineered extracellular vesicles in the preparation of drugs
[0057] In a fourth aspect, the present invention provides the use of engineered extracellular capsules in the preparation of drugs. The CRISPR system in the drug of the present invention edits target genes in target cells, reprograms exhausted T cells, and enhances the anti-tumor immunotherapy effect of liver cancer.
[0058] Example 1
[0059] Construction of engineered EVs delivery system fusion plasmid and donor cell line.
[0060] First, HEK293T cells were co-transfected with plenti-Cas9 plasmid (purchased from lentiCRISPR v2 (Addgene, #52961)) and packaging plasmid, and the stable transfected cell line Cas9 / HEK293T cells was obtained by puromycin selection. Then, the engineered EVs delivery system fusion plasmid was constructed. The PD-1 scFv (human / mouse, Table 1) and flexible peptide (GGGGS) were added to the fusion sequence encoding LAMP2-AcGFP, and the cloned lentiviral plasmid (plenti TPCLG, Figure 1A) was transfected with packaging plasmids (pMDLg / pRRE (Addgene#12251), pRSV-Rev (Addgene#12253), pMD2.G (Addgene#12259)) and infected with the constructed Cas9 / HEK293T cells, and the stable expression cell line (TPCLGC9-293) was further screened using blasticidal toxin (Blasticidin). Green fluorescence was observed by fluorescence microscopy to determine that the fusion protein was localized on the cytoplasmic membrane ( Figure 1 B in the figure). We named the secreted vesicles TPCLGC9-293EVs. Figure 1 A) The constructed cell line was used as a control and named LGC9-293 cells, and the vesicles secreted by it were LGC9-293 EVs.
[0061] Table 1 Human and mouse anti-PD-1 scFv peptide sequences
[0062]
[0063] The culture medium was collected, and EVs were obtained by ultracentrifugation and purified and characterized ( Figure 2 A in the figure). The engineered EVs obtained were confirmed to be round, bilayer-surrounded nanovesicles with a particle size of about 150-300 nm and loaded with Cas9 protein ( Figure 2 BE in ).
[0064] The characterization results of engineered mEVs expressing mouse-derived PD-1 affibody were similar.
[0065] Example 2
[0066] Engineered EVs mediate PD-1 specific targeting.
[0067] To explore the specific targeting of PD-1 mediated by engineered EVs, purified engineered EVs were co-cultured with induced exhausted T cells. The results showed that EVs with anti-PD-1affibody (AcGFP + ) are enriched in PD-1 high expression (PerCP + ), while the control EVs with only LAMP2 did not show any tendency, indicating that the constructed engineered EVs can specifically target PD-1 high-expressing T cells ( Figure 3AB in the figure). At the same time, a mouse subcutaneous tumor model was constructed, and the two engineered EVs were stained and injected into the tumor-bearing mice through the tail vein. After 2 hours, the distribution of the two engineered EVs in the mice was observed using a small animal imaging system; the results showed that EVs carrying anti-PD-1affibody were enriched faster in the mouse tumor site, showing good in vivo targeting characteristics ( Figure 3 in the CD).
[0068] Example 3
[0069] Engineered EVs mediate specific targeting of liver cancer cells.
[0070] To explore the specific targeting of engineered EVs based on HN3-GPC3, GPC3 was + mcherry + Huh7 hepatoma cells and GPC3 - mcherry - LO2 hepatocyte co-culture ( Figure 3 The results showed that EVs with HN3 (HB-EVs, PKH67 staining, green) were expressed in Huh7 liver cancer cells with high expression of GPC3 (mcherry + , red), while control EVs (NC) expressing only LAMP2b did not show any tendency ( Figure 3 B&C in Figure 1), indicating that EVs carrying HN3 can specifically target GPC3-high-expressing liver cancer cells. Similarly, in subcutaneous transplanted tumors in mice, the two engineered EVs were stained (PKH26 staining, red) and then injected into tumor-bearing mice via the tail vein. After 2 hours, the distribution of the two EVs in the mice was observed using the small animal imaging system (IVIS) ( Figure 3 D). The results showed that EVs carrying the HN3 targeting peptide were more rapidly enriched in mouse tumor sites, demonstrating good in vivo targeting characteristics.
[0071] Example 4
[0072] Construction of in vitro induced exhausted T cell model.
[0073] To explore the in vitro editing effects mediated by engineered EVs, we first constructed an in vitro induced T cell exhaustion model, that is, in vitro induced T cell exhaustion to obtain PD-1 high-expressing exhausted T cells. PBMCs were isolated from the peripheral blood of healthy volunteers, and the extracted PBMCs were stimulated multiple times using Dynabeads to simulate the long-term antigen exposure stimulation conditions experienced by T cells in the tumor microenvironment. At different time points, the supernatant of PBMCs culture medium was collected, and IFN-γ and IL-2 effector factor ELSIA detection was performed ( Figure 4 The results showed that as the number of stimulations increased, the levels of these two factors in the cell culture medium increased first and then gradually decreased; and after continuous stimulation, the levels of these two factors in the culture medium were basically the same as those of cells that did not receive stimulation ( Figure 4 At the same time, PBMCs that had been stimulated with magnetic beads for multiple times were stained by flow cytometry and tested on the machine, and it was found that they showed upregulated PD-1 + TIM3 + Phenotype, namely the exhaustion phenotype ( Figure 4 D).
[0074] Example 5
[0075] Engineered EVs mediate gene editing in exhausted T cells.
[0076] In order to explore the gene editing of exhausted T cells mediated by engineered EVs, multiple sgRNA sequences were designed for the research object DUSP2 in this project (Table 2). The sequences with low off-target effects were selected through the online off-target prediction tool and cloned into the sgRNA empty plasmid vector. At the same time, the sgRNA was injected into the engineered EVs by electroporation, and after incubation with the target cells for 48 hours, the T7 nuclease analysis method was used to detect that the above sgRNAs obtained different degrees of gene editing efficiency in the cells ( Figure 5 For the two sgRNAs with relatively high editing efficiency, we extracted the total protein of the cells treated with them and performed WB detection. It can be seen that they have a significant inhibitory effect on DUSP2 protein expression, among which the sg2.2 sequence is particularly obvious ( Figure 5 B in the figure). Therefore, the sg2.2 sequence was selected for subsequent studies (the mouse sgRNA went through the same steps and was finally selected as sg2.6). For the above-constructed exhausted T cell model, engineered EVs and engineered EVs+sgRNA were co-cultured, and the cells and culture supernatant were collected. The results showed that after treatment with engineered EVs+sgRNA, PD-1 + The T cell population was significantly downregulated and the population expressing the cell stemness marker TCF7 was significantly increased ( Figure 5 On the other hand, ELISA results showed that IFN-γ, IL-2 and Grazyme B (CD4 + and CD8 + The secretion of effector factors such as T cell secretion) increased significantly ( Figure 5EG in). At the same time, cell RNA was extracted to analyze the expression of the target gene DUSP2 and related genes such as cell exhaustion markers (LAG3, CTLA4, PD-1, TIM3) and stemness markers (TCF7, CCR7, SOX2). It was found that the expression of the target gene DUSP2 was significantly inhibited after CRISPR editing mediated by engineered EVs. At the same time, the downregulation of exhaustion markers such as PD-1 in this experimental group was accompanied by the upregulation of stemness markers ( Figure 5 In summary, by inhibiting the expression of DUSP2, the phenotype of exhausted T cells was reversed to a certain extent, and they were transformed in the direction of stemness.
[0077] Table 2 Design of sgRNA sequences targeting target gene DUSP2 (human / mouse)
[0078]
[0079] Example 6
[0080] Engineered EVs enhance the killing effect of liver cancer cells in vitro.
[0081] In order to explore the effect of engineered EVs on enhancing the immune killing of liver cancer tumor cells in vitro, liver cancer cells and in vitro induced exhausted T cells were co-cultured in different proportions. Engineered EVs+sg2.2 were added to the culture conditions, and the killing effect of immune cells on liver cancer cells was detected by lactate dehydrogenase (LDH) kit after 48 hours. When the effector-target ratio was 1:5, the highest liver cancer cell killing efficiency was obtained. The above results show that engineered vesicles can reactivate exhausted T cells and kill liver cancer cells.
[0082] It should be noted that the above content only illustrates the technical idea of the present invention and cannot be used to limit the protection scope of the present invention. For ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications all fall within the protection scope of the claims of the present invention.
Claims
1. An engineered vesicle for targeted editing of T cells, characterized in that: The engineered vesicle comprises a lipid bilayer and a Cas protein of the CRISPR system, and the Cas protein enters the vesicle by overexpression of donor cells.
2. An engineered vesicle for targeted editing of T cells according to claim 1, characterized in that The engineered vesicles are obtained by expression and separation of engineered cells transfected with a recombinant expression vector, wherein the recombinant expression vector comprises a first recombinant plasmid and a second recombinant plasmid, wherein the first recombinant plasmid is a nucleic acid sequence encoding a Cas protein of the CRIPSR system; and the second recombinant plasmid comprises a nucleic acid sequence of a fusion protein of a targeting peptide-transmembrane protein of PD-1.
3. An engineered vesicle for targeted editing of T cells according to claim 1, characterized in that The Cas protein includes Cas9 protein or its mutant.
4. A method for preparing an engineered vesicle for targeted editing of T cells as claimed in any one of claims 1 to 3, characterized in that: The following steps are involved: (1) Construction of Cas9 overexpressing cell lines: co-transfecting the recombinant plasmid encoding Cas9 protein and the viral packaging plasmid into HEK-293T cells, obtaining the virus and infecting the host cells, and then culturing and drug screening were performed to screen out cell lines that stably overexpressed Cas9 protein; (2) constructing a recombinant vector: connecting the nucleic acid sequence of the fusion protein of the targeting peptide-transmembrane protein targeting PD-1 to construct a recombinant plasmid; (3) co-transfecting the recombinant plasmid obtained in step (2) and the viral packaging plasmid into the cell line stably overexpressing the Cas9 protein obtained in step (1), obtaining the virus and then infecting the host cells, and culturing and drug screening are performed to screen out a stable engineering donor cell line; (4) isolating engineered extracellular vesicles from the stable engineered donor cell line screened in step (3), and loading sgRNA into the vesicles by electroporation to obtain engineered vesicles that target and edit T cells.
5. The method for preparing an engineered vesicle for targeted editing of T cells according to claim 4, characterized in that: In step (2), the targeting peptide targeting PD-1 includes a human PD-1 targeting peptide and a mouse PD-1 targeting peptide.
6. The method for preparing an engineered vesicle for targeted editing of T cells according to claim 4, characterized in that: In step (4), the sgRNA is a recombinant plasmid, including integrating the target sequence targeting the target gene DUSP2 into the recombinant plasmid.
7. A system for targeted reprogramming of exhausted T cells, characterized in that: It comprises the engineered extracellular vesicle and virus packaging vector as described in any one of claims 1 to 3.
8. Use of the engineered extracellular vesicles according to any one of claims 1 to 3 in the preparation of gene drugs for enhancing anti-tumor immunotherapy of liver cancer.
Citation Information
Cited By
Engineered cell vesicle, preparation method thereof and application of engineered cell vesicle in preparation of antitumor drugs
CN121648315A
